Junko Yokokawa
Fukushima Medical University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Junko Yokokawa.
Hepatology Research | 2010
Atsushi Takahashi; Kazumichi Abe; Junko Yokokawa; Haruyo Iwadate; Hiroko Kobayashi; Hiroshi Watanabe; Atsushi Irisawa; Hiromasa Ohira
Aim: Liver dysfunction is not rare in patients with collagen disease. We sought to elucidate the clinical features of liver dysfunction in the presence of collagen disease.
Hepatology Research | 2011
Atsushi Tanaka; Kenichi Harada; Hirotoshi Ebinuma; Atsumasa Komori; Junko Yokokawa; Kaname Yoshizawa; Masanori Abe; Yasuhiro Miyake; Kentaro Kikuchi; Hiromasa Ohira; Mikio Zeniya; Kazuhide Yamamoto; Hiromi Ishibashi; Morikazu Onji; Yasuni Nakanuma; Hirohito Tsubouchi; Hajime Takikawa
Aims: Primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) may simultaneously coexist in some patients, designated as PBC‐AIH overlap syndrome. Previous studies suggest that combination therapy of ursodeoxycholic acid (UDCA) and corticosteroids may be effective. In the current study, we aimed to describe clinical features of these cases and to propose a rationale for combination treatment in PBC‐AIH overlap.
Journal of Gastroenterology and Hepatology | 2010
Junko Yokokawa; Hironobu Saito; Yukiko Kanno; Fumiko Honma; Kyoko Monoe; Natsumi Sakamoto; Kazumichi Abe; Atsushi Takahashi; Hirohide Yokokawa; Hiromasa Ohira
Background: Coexistence of primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) is referred to as PBC‐AIH overlap. Pathogenesis of PBC‐AIH is not well understood and its diagnosis is challenging. We previously reported the clinical characteristics of 10 patients diagnosed with PBC‐AIH overlap.
Hepatology Research | 2011
Junko Yokokawa; Yukiko Kanno; Hironobu Saito; Kazumichi Abe; Atsushi Takahashi; Hirohide Yokokawa; Hiromasa Ohira
Aim: Patients receiving corticosteroid therapy on a tapered schedule occasionally suffer autoimmune hepatitis (AIH) relapses. The aim of this study was to assess the frequency and features of relapses, explore risk factors associated with relapses, and evaluate the effectiveness of azathioprine (AZP) therapy against relapses in Japanese patients with type 1 AIH.
World Journal of Hepatology | 2012
Kazumichi Abe; Yukiko Kanno; Ken Okai; Fumiko Katsushima; Kyoko Monoe; Hironobu Saito; Atsushi Takahashi; Junko Yokokawa; Hiromasa Ohira
AIM To compare clinicopathological features of acute presentation of type 1 autoimmune hepatitis (AIH) with or without centrilobular necrosis (CN). METHODS Our study comprised 41 patients with biopsy-proven acute presentation (acute exacerbation phase 36, acute hepatitis phase 5) of type 1 AIH at our hospital from 1975 to 2009. Elevated serum alanine aminotransferase (ALT) (> 5x upper limit of normal) identified acute presentation of the disease. We compared clinicopathological features of these AIH patients with or without CN. The data used for analysis included patient background (age, sex, type of disease, presence of complications with other autoimmune diseases, human leukocyte antigen, and International Autoimmune Hepatitis Group score), clinical parameters at presentation (ALT, alkaline phosphatase, IgG, anti-nuclear antibodies, and anti-smooth muscle antibodies), histology and therapy. RESULTS CN was found in 13 (31.7%) patients with acute presentation (acute exacerbation phase 10, acute hepatitis phase 3) of AIH. Serum IgG levels of patients with CN were significantly lower than those of patients without CN (mean: 2307 mg/dL vs 3126 mg/dL, P < 0.05), while antinuclear antibody-negative rates were significantly higher (30.7% vs 3.5%, P < 0.05). However, other clinical features were similar between the two groups. The frequency of advanced fibrosis in patients with CN was significantly lower than in patients without CN (F0-2: 84.6% vs 35.7%, F3-4: 15.4% vs 64.3%, P < 0.05). Other histological features were similar between the two groups. Although there was no significant difference between groups when evaluated using the revised original score (12 vs 14), the simplified AIH score of patients with CN was significantly lower (6 vs 7, P < 0.05). Frequency of DR4 was similar between patients with and without CN. CONCLUSION CN is observed in both Japanese patients with acute hepatitis phase and acute exacerbation phase of type 1 AIH, although AIH with CN often shows clinical features of the genuine acute form.
Hepatology Research | 2007
Atsushi Takahashi; Tsuyoshi Rai; Michio Onizawa; Kyoko Monoe; Yukiko Kanno; Hironobu Saito; Kazumichi Abe; Junko Yokokawa; Atsushi Irisawa; Hiromasa Ohira
A 69‐year‐old man with autoimmune hepatitis (AIH) was admitted to hospital with high fever and cough. Chest roentgenogram and computed tomography showed pleural and pericardial effusion. Serological tests showed a high titer of antinuclear antibodies and positive anti‐DNA antibody and lymphocytopenia. He fulfilled the American College of Rheumatology criteria for systemic lupus erythematosus (SLE). After administration of corticosteroids, his symptoms and liver dysfunction improved. To the authors’ knowledge, this is the first male case of overlap between AIH and late‐onset SLE.
Hepatology Research | 2014
Junko Yokokawa; Yukiko Kanno; Kazumichi Abe; Hironobu Saito; Kyoko Monoe; Fumiko Katsushima; Natsumi Sakamoto; Atsushi Takahashi; Hirohide Yokokawa; Hiromasa Ohira
To assess the prevalence of autoantibodies against nucleosomes (anti‐nucleosome Ab) in patients with autoimmune hepatitis (AIH), examine the correlation between anti‐nucleosome Ab and disease activity, and evaluate the effectiveness of anti‐nucleosome Ab in predicting relapse.
Gastroenterology | 2003
Kazumichi Abe; Hiromasa Ohira; Hiroko Kobayashi; Tsuyoshi Rai; Junko Yokokawa; Junko Takiguchi; Shoichiro Shishido; Yukio Sato
OBJECTIVE To investigate the effects of an intradermal injection of oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs on concanavalin A (Con A)-induced hepatitis, an experimental model of immune-mediated hepatitis. METHODS Con A was injected intravenously into Balb/c mice. Twelve hours after Con A challenge, blood and liver samples were obtained. CpG ODN was injected intradermally 48 hours before Con A challenge. The extent of liver injury was assessed by determining serum alanine transaminase (ALT) and by liver histology. Serum levels of cytokines, including interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha, interleukin (IL)-4 and IL-5, were measured by enzyme-linked immunosorbent assay. RESULTS Co-administration of Con A and CpG ODN significantly increased serum ALT in mice compared with that in the case of administration of Con A alone (10,268 +/- 4,654 and 1,140 +/- 832 IU/1, respectively, p<0.05). In liver histology, mice treated with CpG ODN and Con A showed more extensive midzonal necrosis than did mice treated with Con A alone. These mice also showed significant increases in serum TNF-alpha and IFN-gamma and decrease in serum IL-5. CONCLUSIONS The results indicate that CpG ODNs aggravate Con A-induced hepatitis by stimulating the production of T-helper-1 (Th1) cytokines, TNF-alpha and IFN-gamma, suggesting that bacterial DNA that contains unmethylated CpG motifs may contribute to the exacerbation of immune-mediated liver injury.
Hepatology Research | 2004
Hiromasa Ohira; Junko Takiguchi; Tsuyoshi Rai; Kazumichi Abe; Junko Yokokawa; Yukio Sato; Isao Takeda; Takashi Kanno
Internal Medicine | 2004
Jun Tojo; Hiromasa Ohira; Kazumichi Abe; Junko Yokokawa; Junko Takiguchi; Tsuyoshi Rai; Shoichiro Shishido; Yukio Sato; Reiji Kasukawa